CERMOOD: Cerebellar Stroke and Mood Disorders

Sponsor
University Hospital, Bordeaux (Other)
Overall Status
Completed
CT.gov ID
NCT03515486
Collaborator
(none)
38
1
1
50.4
0.8

Study Details

Study Description

Brief Summary

Post-stroke mood disorders (PSMD), including depression, anxiety and apathy, are observed in about 30 % of stroke patients at follow-up 3 or 4 months after stroke occurrence. They impair the functional outcome of the patients and their quality of life. Among the different brain structures involved in PSMD the role of the cerebellum has been under-evaluated while it is now well-known to be involved in mood regulation. The aim of this study will be to describe the characteristics of early and late mood disorders following a first acute ischemic cerebellar stroke using face to face interviews and mobile technologies and investigate their pathophysiological mechanisms through advanced brain Magnetic resonance imaging (MRI) evaluation of cortico-cerebello-cortical morphological and functional connectivity.

Condition or Disease Intervention/Treatment Phase
  • Other: Post stroke mood disorders evaluation
N/A

Detailed Description

Stroke is the leading cause of acquired disability in adults. Beyond these physical consequences, stroke is a major cause of mood disorders (depression, anxiety, apathy), affecting more than 30% of patients at 3 months after the initial accident. These mood disorders impair patient's quality of life and their post-stroke functional recovery. Their detection is usually based on an interview conducted during a follow-up visit and intensity is measured through dedicated scales. However the sensitivity of these assessments could be improved by multiple daily ecological assessments carried out in the patient environment through mobile technologies such as smartphones (Experience Sampling Method) and actimeters. Moreover, a better understanding of the pathophysiological mechanisms underlying the presence of post-stroke mood disorders could improve their management. Clinical factors such as the severity of the disability or the female gender are associated with the occurrence of mood disorders but the independent role of the anatomical location of brain injury remains uncertain. During the last decade many studies have suggested the role of the cerebellum in the regulation of cognition and, to a lesser extent, mood. An anatomical or functional impairment of the cortico-cerebellar-cortical loops might contribute to the occurrence of the mood disorders observed in some patients with cerebellar lesion.

The aim of this project is to explore in the context of a cerebellar infarct the transverse association between the presence of post-stroke mood disorders, detected both by standard evaluations and assessments conducted in the ecological environment, and the functional and structural alteration of cortico-cerebellar-cortical loops evaluated by MRI.

Study Design

Study Type:
Interventional
Actual Enrollment :
38 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Cerebellar Stroke and Mood Disorders
Actual Study Start Date :
Jan 16, 2017
Actual Primary Completion Date :
Mar 30, 2021
Actual Study Completion Date :
Mar 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Post-stroke mood disorders evaluation

Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations.

Other: Post stroke mood disorders evaluation
Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations

Outcome Measures

Primary Outcome Measures

  1. Center of Epidemiological Studies-Depression scale (CES-D) [Day 0]

    Evaluation of depressive syndrome defined by a score> 17 for men and> 23 for women according to the CES-D

  2. Beck Anxiety Inventory (BAI) [Day 0]

    Evaluation of anxiety disorder defined by a score> 22 on the BAI scale

  3. Apathy Inventory (AI) [Day 0]

    Apathetic syndrome defined by a score > 2 on AI.

Secondary Outcome Measures

  1. Experience Sampling Method (ESM) evaluations [During 7 days]

    Evaluation of daily-life mood disorders using one-week Experience Sampling Method (ESM) evaluations (smartphone)

  2. Actimetry [During 7 days]

    Circadian rhythms : sleep fragmentation and relative amplitude of circadian rhythms measured using one-week actimetry.

  3. Trait-Meta-Mood-Scale (TMMS) [Day 0]

    Evaluation of emotional dysregulation

  4. Trait-Meta-Mood-Scale (TMMS) [24 to 48 months]

    Evaluation of emotional dysregulation

  5. Interpersonal Reactivity Index (IRI) [Day 0]

    Evaluation of emotional dysregulation

  6. Interpersonal Reactivity Index (IRI) [24 to 48 months]

    Evaluation of emotional dysregulation

  7. Facial emotion recognition tests [Day 0]

    Evaluation of emotional dysregulation

  8. Facial emotion recognition tests [24 to 48 months]

    Evaluation of emotional dysregulation

  9. Brain Magnetic Resonance Imaging [Day 0]

    Indexes of the structural and functional integrity of emotional regulation networks

  10. Center of Epidemiological Studies-Depression scale (CES-D) [24 to 48 months]

    Evaluation of depressive syndrome defined by a score> 17 for men and> 23 for women according to the CES-D

  11. Beck Anxiety Inventory (BAI) [24 to 48 months]

    Evaluation of anxiety disorder defined by a score> 22 on the BAI scale

  12. Apathy Inventory (AI) [24 to 48 months]

    Apathetic syndrome defined by a score > 2 on AI.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria :
  • Patients with a first ischemic stroke affecting the cerebellum and returning to a post-visit AVS at 4 ± 1 month

  • Age > 18 ans

  • Modified Rankin Scale pre-stroke ≤ 1

Exclusion Criteria :
  • History of central neurological disorder

  • Pre-stroke cognitive impairment (IQ-code> 3.3) or post-stroke cognitive disorder defined by a MoCA < 24

  • History of mood disorders history in the 6 months prior stroke (clinical screening)

  • Moderate to severe leukoencephalopathy (Fazekas score ≥ 2 )

  • Unable to use a smartphone (aphasia, visual disorder…)

  • Participation in a pharmacological protocol involving psychotropic drugs (anxiolytics, antidepressants, antipsychotics) or a non-pharmacological protocol involving psychotherapeutic management

  • Pregnancy

  • MRI contra-indication(pacemaker, claustrophobia ...)

  • Non affiliated to the French social insurance

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Bordeaux Bordeaux France 33 076

Sponsors and Collaborators

  • University Hospital, Bordeaux

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT03515486
Other Study ID Numbers:
  • CHUBX 2015/36
First Posted:
May 3, 2018
Last Update Posted:
Jul 16, 2021
Last Verified:
Jul 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Bordeaux
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2021